- Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis – - REGAL Independent Data Monitoring Committee…
– Marks first time as a public company that Conavi is presenting at an investor event – – Live webcast…
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of…
WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been…
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal…
FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY…
Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist…
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of…
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem BiosciencesBELTSVILLE, Md., Dec. 10, 2024…
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT)…